AbCellera Biologics Inc. ABCL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Product | |||||
| Research fees | $27.21M+3.5% | $26.28M-26.1% | $35.56M-12.9% | $40.8M+114% | |
| Total Revenue by Geography | |||||
| Canada | $64M+144% | $26.2M-27.2% | $36M-92.6% | $484.2M+37.0% | |
| United States | $11.1M+311% | $2.7M+35.0% | $2M+66.7% | $1.2M-94.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbCellera Biologics Inc. break its business down?
- AbCellera Biologics Inc. (ABCL) reports total revenue by product across 2 parts — Licensing and royalty revenue and Research fees. Each is extracted from the segment footnotes and tracked over time.
- Where does AbCellera Biologics Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbCellera Biologics Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.